Skip to main content
Top
Published in: Clinical and Experimental Nephrology 1/2018

01-02-2018 | Original article

Impact of low-density lipoprotein cholesterol on decline in estimated glomerular filtration rate in apparently healthy young to middle-aged working men

Authors: Akihiro Kuma, Bungo Uchino, Yoko Ochiai, Masatoshi Kawashima, Kazuhiko Enta, Masahito Tamura, Yutaka Otsuji, Akihiko Kato

Published in: Clinical and Experimental Nephrology | Issue 1/2018

Login to get access

Abstract

Background

It remains to be fully clarified whether there is a relationship between uncontrolled dyslipidemia and decline in estimated glomerular filtration rate (eGFR) in the general population. Therefore, this study’s aim was to test the association of dyslipidemia with changes in eGFR in apparently healthy working men.

Methods

We retrospectively examined the annual medical check-up list of 14,510 male workers aged 20–60 years with eGFR ≥ 60 mL/min/1.73 m2 at baseline, and then evaluated the association of the changes in the check-up parameters with a decline in eGFR during the 5-year observation period.

Results

Mean age and eGFR were 38.5 years and 82.3 mL/min/1.73 m2 at baseline, respectively. Evaluated low-density lipoprotein cholesterol (LDL-C) (≥140 mg/dL) was a strong indicator of CKD development in participants (basal eGFR 60–90 mL/min/1.73 m2) without hypertension [odds ratio (95% confidence interval): 1.46 (1.12–1.90)] or diabetes mellitus (DM) [1.49 (1.23–1.82)]. When LDL-C normalized under 140 mg/dL during follow-up, the decline in eGFR was smaller in non-hypertensive participants [−5.9 (−14.4 to −0.9) vs −13.4 (−18.4 to −4.5) mL/min/1.73 m2, p < 0.05]. There was an inverse correlation between change of LDL-C and decline in eGFR (p for trend <0.001).

Conclusion

Increased LDL-C levels are associated with the development of incident CKD and eGFR decline in young to middle-aged working men without hypertension and/or DM.
Appendix
Available only for authorised users
Literature
1.
go back to reference Thomas G, Sehgai AR, Kashyap SR, Srinivas TR, Kirwan JP, Navaneethan SD. Metabolic syndrome and kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2011;6:2364–73.CrossRefPubMedPubMedCentral Thomas G, Sehgai AR, Kashyap SR, Srinivas TR, Kirwan JP, Navaneethan SD. Metabolic syndrome and kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2011;6:2364–73.CrossRefPubMedPubMedCentral
2.
go back to reference Ninomiya T, Kiyohara Y, Kubo M, Yonemoto Y, Tanizaki Y, Doi Y, et al. Metabolic syndrome and CKD in a general Japanese population: The Hisayama Study. Am J Kidney Dis. 2006;48:383–91.CrossRefPubMed Ninomiya T, Kiyohara Y, Kubo M, Yonemoto Y, Tanizaki Y, Doi Y, et al. Metabolic syndrome and CKD in a general Japanese population: The Hisayama Study. Am J Kidney Dis. 2006;48:383–91.CrossRefPubMed
3.
go back to reference O’Seaghdha CM, Hwang SJ, Upadhyay A, Meigs JB, Fox CS. Predictors of incident albuminuria in the Framingham Offspring cohort. Am J Kidney Dis. 2010;56:852–60.CrossRefPubMedPubMedCentral O’Seaghdha CM, Hwang SJ, Upadhyay A, Meigs JB, Fox CS. Predictors of incident albuminuria in the Framingham Offspring cohort. Am J Kidney Dis. 2010;56:852–60.CrossRefPubMedPubMedCentral
4.
go back to reference Tsuruya K, Yoshida H, Nagata M, Kitazono T, Iseki K, Iseki C, et al. Impact of the triglycerides to high-density lipoprotein cholesterol ratio on the incidence and progression of CKD: a longitudinal study in a large Japanese population. Am J Kidney Dis. 2015;66:972–83.CrossRefPubMed Tsuruya K, Yoshida H, Nagata M, Kitazono T, Iseki K, Iseki C, et al. Impact of the triglycerides to high-density lipoprotein cholesterol ratio on the incidence and progression of CKD: a longitudinal study in a large Japanese population. Am J Kidney Dis. 2015;66:972–83.CrossRefPubMed
5.
go back to reference van der Velde M, Matsushita K, Coresh J, Astor BC, Woodward M, Levey A, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int. 2011;79:1341–52.CrossRefPubMed van der Velde M, Matsushita K, Coresh J, Astor BC, Woodward M, Levey A, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int. 2011;79:1341–52.CrossRefPubMed
6.
go back to reference Hillege HL, Fidler V, Diercks GF, van Gilst WH, de Zeeuw D, van Veldhuisen DJ, et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation. 2002;106:1777–82.CrossRefPubMed Hillege HL, Fidler V, Diercks GF, van Gilst WH, de Zeeuw D, van Veldhuisen DJ, et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation. 2002;106:1777–82.CrossRefPubMed
7.
go back to reference Hallan SI, Matsushita K, Sang Y, Mahmoodi BK, Black C, Ishani A, et al. Age and association of kidney measures with mortality and end-stage renal disease. JAMA. 2012;308:2349–60.CrossRefPubMedPubMedCentral Hallan SI, Matsushita K, Sang Y, Mahmoodi BK, Black C, Ishani A, et al. Age and association of kidney measures with mortality and end-stage renal disease. JAMA. 2012;308:2349–60.CrossRefPubMedPubMedCentral
8.
go back to reference Kidney Disease. Improving Global Outcomes (KDIGO) Lipid Work Group. KDIGO clinical practice guideline for lipid management in chronic kidney disease. Kidney Int. 2013; Suppl 3:259–305. Kidney Disease. Improving Global Outcomes (KDIGO) Lipid Work Group. KDIGO clinical practice guideline for lipid management in chronic kidney disease. Kidney Int. 2013; Suppl 3:259–305.
9.
go back to reference Yamagata K, Ishida K, Sairenchi T, Takahashi H, Ohba S, Shiigai T, et al. Risk factors for chronic kidney disease in a community-based population: a 10-year follow-up study. Kidney Int. 2007;71:159–66.CrossRefPubMed Yamagata K, Ishida K, Sairenchi T, Takahashi H, Ohba S, Shiigai T, et al. Risk factors for chronic kidney disease in a community-based population: a 10-year follow-up study. Kidney Int. 2007;71:159–66.CrossRefPubMed
10.
go back to reference D’Adamo E, Santoro N, Caprio S. Metabolic syndrome in pediatrics: old concepts revised, new concepts discussed. Endocrinol Metab Clin N Am. 2009;38:549–63.CrossRef D’Adamo E, Santoro N, Caprio S. Metabolic syndrome in pediatrics: old concepts revised, new concepts discussed. Endocrinol Metab Clin N Am. 2009;38:549–63.CrossRef
11.
go back to reference Vrdoljak A, Ivkovic V, Karanovic S, Dika Z, Domislovic V, Dapic K, et al. Glomerular hyperfiltration as a risk factor for renal impairment and hypertension in apparently healthy subjects. J Hypertens. 2016;34(Suppl 2):e19.CrossRef Vrdoljak A, Ivkovic V, Karanovic S, Dika Z, Domislovic V, Dapic K, et al. Glomerular hyperfiltration as a risk factor for renal impairment and hypertension in apparently healthy subjects. J Hypertens. 2016;34(Suppl 2):e19.CrossRef
12.
go back to reference Moriya T, Tanaka S, Sone H, Ishibashi S, Matsunaga S, Ohashi Y, et al. Patients with type 2 diabetes having higher glomerular filtration rate showed rapid renal function decline followed by impaired glomerular filtration rate: Japan Diabetes Complications Study. J Diabetes Complicat. 2016. doi:10.1016/j.jdiacomp.2016.06.020. Accessed 29 Jun 2016. Moriya T, Tanaka S, Sone H, Ishibashi S, Matsunaga S, Ohashi Y, et al. Patients with type 2 diabetes having higher glomerular filtration rate showed rapid renal function decline followed by impaired glomerular filtration rate: Japan Diabetes Complications Study. J Diabetes Complicat. 2016. doi:10.​1016/​j.​jdiacomp.​2016.​06.​020. Accessed 29 Jun 2016.
13.
go back to reference Matsumoto I, Miyake Y, Mizukawa M, Takagi Y. Impact of low-density lipoprotein cholesterol/high-density lipoprotein cholesterol ratio on long-term outcome in patients undergoing percutaneous coronary intervention. Circ J. 2011;75:905–10.CrossRefPubMed Matsumoto I, Miyake Y, Mizukawa M, Takagi Y. Impact of low-density lipoprotein cholesterol/high-density lipoprotein cholesterol ratio on long-term outcome in patients undergoing percutaneous coronary intervention. Circ J. 2011;75:905–10.CrossRefPubMed
14.
15.
go back to reference Tonelli M, Muntner P, Lloyd A, Manns B, Klarenbach S, Pannu N, et al. Association between LDL-C and risk of myocardial infarction in CKD. J Am Soc Nephrol. 2013;24:979–86.CrossRefPubMedPubMedCentral Tonelli M, Muntner P, Lloyd A, Manns B, Klarenbach S, Pannu N, et al. Association between LDL-C and risk of myocardial infarction in CKD. J Am Soc Nephrol. 2013;24:979–86.CrossRefPubMedPubMedCentral
16.
go back to reference Keys A, Menotti A, Aravanis C, Blackburn H, Djordevic BS, Buzina R, et al. The seven countries study: 2289 deaths in 15 years. Prev Med. 1984;13:141–54.CrossRefPubMed Keys A, Menotti A, Aravanis C, Blackburn H, Djordevic BS, Buzina R, et al. The seven countries study: 2289 deaths in 15 years. Prev Med. 1984;13:141–54.CrossRefPubMed
17.
go back to reference Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezemitibe in patients with chronic kidney disease (study of heart and renal protection): a randomised placebo-controlled trial. Lancet. 2011;377:2181–92.CrossRefPubMedPubMedCentral Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezemitibe in patients with chronic kidney disease (study of heart and renal protection): a randomised placebo-controlled trial. Lancet. 2011;377:2181–92.CrossRefPubMedPubMedCentral
18.
go back to reference Shepherd J, Kastelein JJ, Bittner V, Deedwania P, Breazna A, Dobson S, et al. Intensive lipid loweiring with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. J Am Coll Cardiol. 2008;51:1448–54.CrossRefPubMed Shepherd J, Kastelein JJ, Bittner V, Deedwania P, Breazna A, Dobson S, et al. Intensive lipid loweiring with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. J Am Coll Cardiol. 2008;51:1448–54.CrossRefPubMed
19.
go back to reference Brenner BM, Cooper ME, Zeeuw DD, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861–9.CrossRefPubMed Brenner BM, Cooper ME, Zeeuw DD, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861–9.CrossRefPubMed
20.
go back to reference Niculescu LS, Sanda GM, Sima AV. HDL inhibits endoplasmic reticulum stress by stimulating apoE and CETP secretion from lipid-loaded macrophages. Biochem Biophys Res Commun. 2013;434:173–8.CrossRefPubMed Niculescu LS, Sanda GM, Sima AV. HDL inhibits endoplasmic reticulum stress by stimulating apoE and CETP secretion from lipid-loaded macrophages. Biochem Biophys Res Commun. 2013;434:173–8.CrossRefPubMed
21.
23.
go back to reference Nakano T, Ninomiya T, Sumiyoshi S, Onimaru M, Fujii H, Itabe H, et al. Chronic kidney disease is associated with neovascularization and intraplaque hemorrhage in coronary atherosclerosis in elders: results from the Hisayama Study. Kidney Int. 2013;84:373–80.CrossRefPubMed Nakano T, Ninomiya T, Sumiyoshi S, Onimaru M, Fujii H, Itabe H, et al. Chronic kidney disease is associated with neovascularization and intraplaque hemorrhage in coronary atherosclerosis in elders: results from the Hisayama Study. Kidney Int. 2013;84:373–80.CrossRefPubMed
24.
go back to reference Muntner P, Coresh J, Smith JC, Eckfeldt J, Klag MJ. Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. Kidney Int. 2000;58:293–301.CrossRefPubMed Muntner P, Coresh J, Smith JC, Eckfeldt J, Klag MJ. Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. Kidney Int. 2000;58:293–301.CrossRefPubMed
25.
go back to reference Fox CS, Larson MG, Leip EP, Culleton B, Wilson PW, Levy D. Predictors of new-onset kidney disease in a community-based population. JAMA. 2004;291:844–50.CrossRefPubMed Fox CS, Larson MG, Leip EP, Culleton B, Wilson PW, Levy D. Predictors of new-onset kidney disease in a community-based population. JAMA. 2004;291:844–50.CrossRefPubMed
26.
go back to reference Hou X, Wang C, Zhang X, Zhao X, Wang Y, Li C, et al. Triglyceride levels are closely associated with mild decline in estimated glomerular filtration rates in middle-aged and elderly Chinese with normal serum lipid levels. PLoS ONE. 2014;9:e106778.CrossRefPubMedPubMedCentral Hou X, Wang C, Zhang X, Zhao X, Wang Y, Li C, et al. Triglyceride levels are closely associated with mild decline in estimated glomerular filtration rates in middle-aged and elderly Chinese with normal serum lipid levels. PLoS ONE. 2014;9:e106778.CrossRefPubMedPubMedCentral
27.
go back to reference Packard CJ, Ford I, Robertson M, Shepherd J, Blauw GJ, Murphy MB, et al. Plasma lipoproteins and apolopoproteins as predictors of cardiovascular risk and treatment benefit in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER). Circulation. 2005;112:3058–65.CrossRefPubMed Packard CJ, Ford I, Robertson M, Shepherd J, Blauw GJ, Murphy MB, et al. Plasma lipoproteins and apolopoproteins as predictors of cardiovascular risk and treatment benefit in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER). Circulation. 2005;112:3058–65.CrossRefPubMed
28.
go back to reference Vidt DG, Ridker PM, Monyak JT, Schreiber MJ, Cressman MD. Longitudinal assessment of estimated glomerular filtration rate in apparently healthy adults: a post hoc analysis from the JUPITER study (justification for the use of statin in prevention: an intervention trial evaluating rousuvastatin). Clin Ther. 2011;33:717–25.CrossRefPubMed Vidt DG, Ridker PM, Monyak JT, Schreiber MJ, Cressman MD. Longitudinal assessment of estimated glomerular filtration rate in apparently healthy adults: a post hoc analysis from the JUPITER study (justification for the use of statin in prevention: an intervention trial evaluating rousuvastatin). Clin Ther. 2011;33:717–25.CrossRefPubMed
29.
go back to reference Rahman M, Yang W, Akkina S, Alpher A, Anderson AH, Appel LJ, et al. Relation of serum lipids and lipoproteins with progression of CKD: the CRIC study. Clin J Am Soc Nephrol. 2014;9:1190–8.CrossRefPubMedPubMedCentral Rahman M, Yang W, Akkina S, Alpher A, Anderson AH, Appel LJ, et al. Relation of serum lipids and lipoproteins with progression of CKD: the CRIC study. Clin J Am Soc Nephrol. 2014;9:1190–8.CrossRefPubMedPubMedCentral
30.
go back to reference Okamura T, Kokubo Y, Watanabe M, Higashiyama A, Miyamoto Y, Yoshimasa Y, et al. Low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol and incidence of cardiovascular disease in an urban Japanese cohort study: the Suita study. Atherosclerosis. 2009;203:587–92.CrossRefPubMed Okamura T, Kokubo Y, Watanabe M, Higashiyama A, Miyamoto Y, Yoshimasa Y, et al. Low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol and incidence of cardiovascular disease in an urban Japanese cohort study: the Suita study. Atherosclerosis. 2009;203:587–92.CrossRefPubMed
Metadata
Title
Impact of low-density lipoprotein cholesterol on decline in estimated glomerular filtration rate in apparently healthy young to middle-aged working men
Authors
Akihiro Kuma
Bungo Uchino
Yoko Ochiai
Masatoshi Kawashima
Kazuhiko Enta
Masahito Tamura
Yutaka Otsuji
Akihiko Kato
Publication date
01-02-2018
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 1/2018
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-017-1407-8

Other articles of this Issue 1/2018

Clinical and Experimental Nephrology 1/2018 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.